Abstract | Nonalcoholic fatty liver disease (NAFLD) is a disorder characterized by excess accumulation of fat in hepatocytes (nonalcoholic fatty liver (NAFL)); in up to 40% of individuals, there are additional findings of portal and lobular inflammation and hepatocyte injury (which characterize nonalcoholic steatohepatitis (NASH)). A subset of patients will develop progressive fibrosis, which can progress to cirrhosis. Hepatocellular carcinoma and cardiovascular complications are life-threatening co-morbidities of both NAFL and NASH. NAFLD is closely associated with insulin resistance; obesity and metabolic syndrome are common underlying factors. As a consequence, the prevalence of NAFLD is estimated to be 10-40% in adults worldwide, and it is the most common liver disease in children and adolescents in developed countries. Mechanistic insights into fat accumulation, subsequent hepatocyte injury, the role of the immune system and fibrosis as well as the role of the gut microbiota are unfolding. Furthermore, genetic and epigenetic factors might explain the considerable interindividual variation in disease phenotype, severity and progression. To date, no effective medical interventions exist that completely reverse the disease other than lifestyle changes, dietary alterations and, possibly, bariatric surgery. However, several strategies that target pathophysiological processes such as an oversupply of fatty acids to the liver, cell injury and inflammation are currently under investigation. Diagnosis of NAFLD can be established by imaging, but detection of the lesions of NASH still depend on the gold-standard but invasive liver biopsy. Several non-invasive strategies are being evaluated to replace or complement biopsies, especially for follow-up monitoring.
Nonalcoholic fatty liver disease (NAFLD) has been accepted as a bona fide disease entity in the late twenti eth century. The disorder is characterized by excess accumulation of fat (in the form of triglycerides) in hepatocytes (>5% fat content in the liver; referred to as steatosis), leading to nonalcoholic fatty liver (NAFL). In the presence of additional factors, described below, hepatocyte injury and cell death occur along with lobu lar and portal inflammation, and the disease is referred to as nonalcoholic steatohepatitis (NASH). With pro gressive collagen deposition and subsequent vascular remodelling, cirrhosis may result.
Several histological features of NAFLD and NASH are common to alcoholic fatty liver disease (AFLD), including steatosis, inflammation, hepatocyte balloon ing (a type of hepatocyte injury), Mallory-Denk bodies (Mallory hyaline) and fibrosis within the lobules (FIG. 1) . However, in contrast to the underlying exposure to excess alcohol that initiates and drives AFLD, patients with NAFLD are insulin resistant, usually obese and do not consume excess alcohol 1 . Interestingly, whereas paediatric NAFLD shares similar metabolic triggers with NAFLD in adults, different patterns of histological injury may be observed 2 
.
Morbidity and mortality in patients with NAFLD can be related to the liver disease itself, although cardio vascular disease is the primary cause of premature death 3, 4 . Cirrhosis and hepatocellular carcinoma (HCC) are the most common liverrelated causes of morbid ity associated with NAFLD, followed by systemic infec tion 5 . HCC has been shown to occur in the absence of cirrhosis, which is a concern for clinical care 6 . Finally, the value of the liver biopsy as a diagnostic tool, although an invasive procedure, continues to be shown by large studies analysing the correlation between longterm outcomes with histopathological evaluation. Advanced fibrosis has been identified as the most impor tant histological feature associated with poor outcomes in two studies 5, 7 ; inflammation is associated with the initi ation and progression of fibrosis 8 . Both in children and in adults, NASHrelated cirrhosis is predicted to become the most common indication for liver transplantation 9 . Several noninvasive diagnostic tools are currently being validated and show promise to replace liver biopsy and identify early fibrosis in the setting of NAFLD.
In this Primer, we describe the worldwide prevalence of NAFLD in adults and children, highlight genomic and epigenomic changes associated with disease and its progression, as well as the molecular drivers of disease, and elaborate on the advances in diagnosis and the cur rent limitations of management options, qualityoflife (QOL) concerns and outline the avenues for progress.
Epidemiology

Adults
The United States and Europe. NAFLD is currently the most common cause of abnormal liver function tests in western countries. According to population studies using ultrasonography or CT imaging, the prevalence of NAFLD is in the range of 20-50% [10] [11] [12] [13] (TABLE 1) . The prevalence of NAFLD varies markedly between eth nic groups. An urban population study in the United States using proton magnetic resonance spectroscopy ( 1 HMRS) showed that the prevalence of hepatic stea tosis was 45% in Hispanic, 33% in white and 24% in black populations 14 . These variations can be explained by differences in lifestyle, the prevalence of metabolic syndrome and genetics, such as a polymorphism of the patatinlike phospholipase domaincontaining 3 (PNPLA3) gene, which encodes a lipase that mediates triacylglycerol hydrolysis in adipocytes (FIG. 2) . NAFLD is strongly associated with metabolic disorders. Not surprisingly, fatty liver has been reported in 40-80% of patients with type 2 diabetes mellitus (T2DM) and 30-90% of patients who are obese 15, 16 . As imaging can only detect fatty liver but not necro inflammation or fibrosis, the prevalence of NASH and the related liver fibrosis in the population is unclear. Histological analyses suggest that 6-55% of patients with NAFLD have NASH, depending on the patient inclusion criteria and the definition of NASH [17] [18] [19] . Nonetheless, patients undergoing liver biopsy are highly selected and are not representative for a community. In a study of 328 unselected patients attending an outpatient clinic in the southwest of the United States, 46% had NAFLD based on patient history and ultrasonography findings 12 . Of those with NAFLD, 134 (out of a total of 156 patients) underwent liver biopsy, of whom 40 were found to have NASH, suggesting a NASH prevalence of 12% in the adults seeking routine health care. Furthermore, using a score validated against liver histology, a Finnish group estimated the population prevalence of NASH to be around 5% 20 .
With ongoing necroinflammation and liver injury, patients with NASH can develop progressive liver fibro sis and, eventually, cirrhosis. Advanced fibrosis or cir rhosis due to NASH has a similar mortality than when these features are caused by chronic hepatitis C virus infection and advanced liver disease. Contributing to this risk of death is the development of HCC. The annual incidence of HCC in patients with NASHrelated cir rhosis is 1-2% 21 . In the United States, NASH has already become the secondleading aetiology of liver disease requiring liver transplantation in adults because of advanced cirrhosis or HCC 22 . Importantly, the number of patients with NASH on the transplantation waiting list increased by 170% from 2004 to 2013, the largest absolute and relative increase compared with other aetiologies. Hepatic complications represent the third most common cause of death in patients with NAFLD or NASH, after cardiovascular events and malignancies 4 .
Asia, Africa and the Pacific Islands. The epidemio logy of NAFLD in AsiaPacific and African countries is shaped by vast differences in lifestyle and economic growth among countries and between urban and rural areas within the same country. For example, in China, the prevalence of NAFLD is higher in coastal and urban areas (up to 30%) than in inland and rural areas (around 1%) 23 . In urban areas, the prevalence of NAFLD is around 15-30% in AsiaPacific countries and 10-20% in Africa.
Compared with western countries, the increase in NAFLD prevalence over time is more marked in Asia and the Pacific areas, probably reflecting rapid lifestyle changes. Studies from Japan and China recorded a two fold increase in the prevalence of NAFLD over a dec ade 23, 24 . By contrast, the reported prevalence of NAFLD in the United States was already around 30-40% in 2004 and has not increased substantially thereafter 14 . The inci dence of NAFLD is difficult to study because ultrasono graphy cannot reliably quantify liver fat. Nevertheless, according to a recent study from Hong Kong using paired 1 HMRS, 13.5% of community subjects devel oped NAFLD in 3-5 years 25 . Asians and Pacific Islanders develop obesityrelated complications at a lower body mass index (BMI) than Europeans and Americans because of the tendency to have central fat accumu lation. As a result, approximately 15-20% of Asian patients with NAFLD do not have obesity according to current definitions.
Data on the prevalence of advanced liver disease in the general AsiaPacific and African populations are scarce. One population study in Hong Kong using tran sient elastography and serum markers of fibrosis suggests that around 4% of patients with NAFLD in the commu nity have advanced fibrosis or cirrhosis 26 . In highrisk groups, such as patients with T2DM, advanced fibrosis and cirrhosis can be found in 10-20% of patients.
Children and adolescents
The United States and Europe. NAFLD is the most com mon liver disease in children and adolescents (TABLE 2) . Similarly to adult patients, NAFLD is associated with obesity and metabolic syndrome 27 and probably with increased levels of alanine aminotransferase (ALT) in the blood and PNPLA3 polymorphisms 28, 29 (FIG. 2) .
A recent analysis of the National Health and Nutrition Examination Survey, including data from >12,000 12-19yearold Americans, showed that the prevalence of NAFLD (with NAFLD defined as a BMI in the >85 th percentile and increased ALT levels of >22.1 U per litre for girls and >25.8 U per litre for boys) more than doubled over the past two decades 27 . The associated risk factors identified in this study confirm previously identi fied factors, such as age, increased BMI, male gender and MexicanAmerican race 30 . Modifiable factors were increased consumption of sugarsweetened beverages and other lifestyle factors (such as a sedentary behav iour) 27 . Paediatric NAFLD prevalence has been predicted to increase even further 31 . Ethnicity also has a role in NAFLD risk in children. Given the similar BMI and metabolic syndrome fea tures, black and nonHispanic children have a lower risk of developing liver disease than Hispanic children (reviewed in REF. 29 ). Hereditability, particularly in first degree relatives, is documented. Indeed, 59% of siblings and 78% of parents of children with fatty liver will also develop NAFLD 32 . Age is another striking factor; one postmortem study in California showed that 17% of teenagers had NAFLD compared with 0.7% of 2-4year olds, owing to both a longer period to accumulate steatosis and an increased incidence in adolescents 30 .
Asia, Africa and the Pacific Islands. Given that over weight and obesity are important risk factors for NAFLD, the prevalence of NAFLD in Korea is greater in patients admitted to obesity clinics (71.9% based on ultrasonography measures and 61.8% based on serum ALT levels) than in general health clinics (8.7% based on ultrasonography measures and 5.9% based on serum ALT levels) 33 . In most of Asia, a significant difference is reported between urban and rural populations, with a prevalence of 16-32% in urban areas versus 9% in rural populations 34 . Obesityrelated NAFLD was reported in 64 out of 84 Chinese children (77%) in one study 35 . In Australia, the prevalence of NAFLD in the paediatric population was estimated to be approximately 10% in the total population and 27.6% among children who are overweight or obese 36 .
Mechanisms/pathophysiology
Pathophysiology of NAFLD Fatty liver disease is characterized by hepatic steatosis; there may also be varying degrees of hepatocyte injury, inflammation and, in some cases, fibrosis (FIG. 1) .
The evolution of hepatic steatosis in obesity. Several fac tors contribute to the accumulation of hepatic lipids in the setting of obesity (FIG. 3) . First, weight gain is associ ated with marked expansion of adipose tissue, which leads to dysfunction and eventual death of adipocytes. Dysfunction of adipose tissue results in local inflam mation and the upregulation of cytokines that promote insulin resistance. Insulin resistance, in turn, compro mises the ability of adipocytes to store fat, resulting in the release of free fatty acids into the circulation, which then become available for uptake by ectopic organs such as the liver 37 . As a consequence of obesityrelated adipose tissue dysfunction, the liver is exposed to high levels of circulating free fatty acids as well as high levels of insulin, which is produced to compensate for sys temic insulin resistance. Hepatocytes take up these fatty acids via the transporters fatty acid transport protein 5 (FATP5; also known as bile acylCoA synthetase) and CD36, which are also upregulated in obesity 38, 39 . Fatty acid accumulation in hepatocytes prompts the synthe sis of triglycerides; during this process, diacylglycerol Steatosis is concentrated in acinar zone 3, the microcirculatory unit through which blood exits the liver around the terminal hepatic venule (in circle) and shows sparing of the periportal, zone 1 hepatocytes, the microcirculatory unit through which portal and systemic blood enter and mix. This is the adult pattern of nonalcoholic fatty liver disease (NAFLD) (trichrome staining). b | Steatohepatitis with marked steatosis (S), ballooning (B), lobular and portal inflammation (I) and extensive bridging fibrosis (haematoxylin and eosin staining). c | Fibrosis in the perisinusoidal spaces of zone 3 is detected by trichrome stain; bridging fibrosis (arrow) is noted between two central veins. Hepatocytes with steatosis are seen, but no ballooned hepatocytes are present. d | Nonalcoholic steatohepatitis (NASH) with cirrhosis, but no active lesions remain. One would only know this was a case of NASH-related cirrhosis by having had a prior biopsy with the diagnosis of active NASH. e | Hepatocellular carcinoma after the development of NASH and cirrhosis.
intermediates accumulate, which impair hepatic insu lin signalling by activating protein kinase Cε (PKCε) 40 . Hepatocyte insulin resistance fuels gluconeogenesis, promoting hyperglycaemia and prompting even more compensatory insulin production.
The liver itself can contribute to hepatic steatosis by producing lipid from carbohydrate in a process called de novo lipogenesis (DNL). The enzymes responsible for DNL are upregulated by insulin and glucose through the action of two transcription factors, sterol regulatory elementbinding protein 1 (SREBP1) and carbohydrate responsive elementbinding protein (ChREBP) 41 . In the normal liver, DNL is not a main source of hepatic lipid, but in the setting of obesity and hyperinsulinaemia, DNL can contribute as much as 25% of total hepatic lipid stores, and is considered an important factor in the development of NAFLD 42, 43 . Why an insulin dependent process such as DNL would be upregulated in hepatocytes if uptake of excess circulating fatty acids has rendered them insulin resistant seems paradoxi cal. One explanation is that hepatocyte insulin resist ance manifests downstream from the insulin receptor 44 ; another is that DNL can also be induced by insulin independent pathways, such as endoplasmic reticulum stressmediated activation of SREBP1 (REF. 45 ).
Nutrients from the diet also serve as substrates for hepatic triglyceride synthesis and thus participate in the development of hepatic steatosis. Dietary sugars are converted to fatty acids via DNL, and dietary fats are taken up by the liver along with adipose tissuederived fatty acids. Roughly 40% of the lipid that accumulates in a fatty liver derives from dietary sugars and fats. Lipolysis of dysfunctional adipose tissue contributes the remaining 60% 43 .
The gut-liver axis in NAFLD. Interactions between the intestine and the liver are emerging as important deter minants of NAFLD. Obesity, which is a key factor con tributing to the development of NAFLD, is associated with alterations in the intestinal microbiota that enhance nutrient extraction from the diet 46 . To date, NAFLD has not yet been linked to any specific microbiotic signa ture, but people with NAFLD have intestinal microbiota that is clearly different from that of healthy individuals 47 .
Intestinal dysbiosis can contribute to liver disease by weakening the intestinal barrier and enabling the trans location of bacteria or bacterial products, such as endo toxin or ethanol, into the portal circulation. Dysbiosis can also lead to the luminal degradation of beneficial nutrients, such as choline, which are important for the maintenance of hepatic lipid homeostasis 11 .
Mechanisms of cell death in a fatty liver. One of the hall marks that differentiates NASH from NAFL is the pres ence of hepatocyte injury. Hepatocytes can be damaged by several mechanisms in the setting of NAFLD (FIG. 3) . First, the demand for metabolism of excess fatty acids places strain on hepatocyte mitochondria; over time this leads to mitochondrial uncoupling, the production of reactive oxygen species (ROS) and the activation of Jun Nterminal kinase (JNK) 48 . Once initiated, ROS pro duction and JNK activation continue in a feedforward loop, which results in mitochondrial damage, impaired ATP production and cell death 49, 50 . Excess fatty acids can also injure hepatocytes by inducing endoplasmic reticulum stress, which leads to mitochondrial dysfunc tion and cell death through caspase2mediated cleav age of BH3interacting domain death agonist (BID) [51] [52] [53] . However, another pathway via which fatty acids can kill hepatocytes is through the activation of death receptors. Several death receptors (such as FAS, death receptor 5 (DR5; also known as TNFRSF10B and TRAILR2) and tumour necrosis factor receptor superfamily member 1A (TNFRSF1A; also known as TNFR1) are upregulated on hepatocytes in the setting of steatosis; the activation of death receptors has been implicated as an impor tant stimulus for hepatocyte apoptosis and necroptosis in NASH [54] [55] [56] [57] .
Inflammation and fibrosis in fatty livers. Activation of the immune system is a key feature of NASH (FIG. 3) . The classic effectors of hepatic inflammation in NASH are Kupffer cells and recruited macrophages, but natu ral killer T cells play an important part in macrophage recruitment 58 , and both natural killer T cells and T cells are emerging as contributors to progressive liver dis ease [59] [60] [61] [62] [63] . Several compounds can trigger inflammation in fatty livers -including fatty acids, bacterial endo toxin reaching the liver from the intestine and damage associated molecular patterns (DAMPs) released from dying hepatocytes -and induce inflammation by acti vating Tolllike receptors (TLRs) and inflammasomes in target immune cells 64, 65 , stimulating the production of an array of cytokines and chemokines 58, 66, 67 . 71 . One unique consideration in NASH is the role of ballooned hepatocytes in hepatic fibrosis. Ballooned cells produce Sonic Hedgehog 72 , a protein that promotes tissue fibrosis 73 . Whether Sonic Hedgehog stimulates fibrosis through direct effects on stellate cells or indirect effects on fatty liver injury is currently under study 74 .
Genetics
A substantial proportion of the population are at risk of progressive NAFLD (that is, progression to NASH with advanced fibrosis or cirrhosis) due to obesity and insu lin resistance. However, only a minority of people with NAFLD progress to moreadvanced disease, including HCC 75 . The reasons for this remain incompletely under stood, but NAFLD is best considered a complex disease trait, the development and progression of which are attributed to subtle interindividual variations, includ ing host genetic factors and environmental factors that interact to produce disease phenotype and determine disease progression. Although the presence of NAFLD is principally determined by environmental factors, genetic factors contribute and, crucially, determine how individuals respond to the challenge of caloric excess and consequent metabolic stressors.
Until 2008, studies looking for genetic vari ants involved in susceptibility to NAFLD had been restricted to case-control allelic association studies limited by the fact that they are reliant on a priori hypotheses for gene selection. Candidate genes are drawn from the limited pool of genes of which biologi cal function is understood and considered relevant to the disease. Only a minority of genes associated with NAFLD through candidate gene analysis have been independently validated in large independent studies or through the use of transmission disequilibrium test ing. This short list includes: mitochondrial super oxide dismutase 2 (SOD2) 76 , phosphatidylethanol amine Nmethyltransferase (PEMT) 77 , fatty acid desatu rase 1 (FADS1) 78 , and Kruppellike factor 6 (KLF6) 79 . All of these genes were associated with progressive NAFLD rather than NAFLD. More recently, several novel genetic associations with NAFLD have been identified through genomewide association studies (GWAS) [80] [81] [82] [83] [84] [85] [86] [87] . Two of these associations are worthy of particular attention owing to their reproducibility in several GWAS, their association with histologically advanced disease in subsequent association studies and their biological plausibility -at least as genes that are clearly involved in hepatic lipid metabolism. The first of these genes encodes PNPLA3 (REF. 80 ). The index singlenucleotide polymorphism (SNP) in PNPLA3 (rs738409; c.444 C>G; p.I148M) is a non synonymous cytosine to guanine nucleotide transver sion mutation that results in an isoleucine to methionine amino acid change at codon 148. A gene dosage effect for PNPLA3
I148M carriage is observed with a stepwise increase in 1 HMRSquantified hepatic triglyceride content with increasing carriage of the minor allele 80 . The minor allele frequency also correlates with ethnic differences in susceptibility to NAFLD. Multiple histo logically based studies have clearly demonstrated that the PNPLA3 I148M variant is associated with the sever ity of steatohepatitis and fibrosis 88 and more recently with the presence of HCC 89 . PNPLA3 might, there fore, be used as part of an HCC surveillance strategy. The PNPLA3 I148M SNP has also been associated with a greater response to dietary or lifestyle modification and may therefore be a biomarker for both greater risk of progressive disease and greater benefit from inter vention. The precise mechanism through which the PNPLA3 I148M SNP contributes to disease remains con troversial despite intensive study, although alterations in lipid droplet architecture and in retinol metabolism of the hepatic stellate cell have been associated with the PNPLA3 I148M variant 90, 91 . The second of these genes encodes transmembrane 6 superfamily member 2 (TM6SF2) on chromosome 19, with a nonsynonymous SNP (rs58542926; c.449 C>T; p.E167K) associated with 1 HMRSquantified hepatic triglyceride content 86 . As with PNPLA3, candidate gene studies have shown that the TM6SF2 E167K variant is also associated with progressive NAFLD 92 . Interestingly, evidence has been provided that carriage of the more common TM6SF2 E167K major allele is associated with dyslipidaemia (that is, increased serum LDL cholesterol and triglyceride levels), increased myocardial infarction and cardiovascular disease risk, whereas minor allele carriage is protective 93 . Functional studies suggest that TM6SF2 regulates hepatic lipid efflux, with its deletion or mutation resulting in a reduction in lipoprotein secre tion (VLDL, triglycerides and apolipoprotein B) leading to increased hepatocellular lipid droplet size and triglyc eride accumulation. The TM6SF2 E167K variant results in lower total cholesterol in humans and expression levels of the variant are lower than the wildtype form. These data indicate that the TM6SF2 E167K variant confers a 'loss of function' to the protein that may be both qualitative and quantitative 93 . Although these studies fail to provide any explan ation for the association between the TM6SF2 variant and progressive NAFLD, they do suggest an interest ing paradox -the 'TM6SF2 Catch22' paradigm 94 . Here, on a background of insulin resistance and meta bolic stress, TM6SF2 genotype acts as a determinant of metabolic syndromerelated endorgan damage and clinical outcome: protecting the liver at the expense of increased risk of atherosclerosis and cardiovascular disease or vice versa. The best evidence in support of this paradigm has recently been provided by a study in patients with NAFLD demonstrating that, although the minor threonine SNP (TM6SF2 E167K ) is associated with advanced disease, carriage of the major cysteine allele ( TM6SF2 167E ) is associated with dyslipidaemia and cardiovascular disease 95 .
Epigenetics
The role of epigenetic factors in the biology of NAFLD is starting to emerge and has enabled integration of information on gene expression with the external and internal metabolic information (FIG. 4) . Epigenetic alter ations orchestrate the reprogramming of transcriptional machinery of hepatocytes, which occurs during their adaptation to a lipotoxic environment, inflammation and oxidative stress. These epigenetic changes could at least partially explain why the degree of histological damage and/or recovery differs among individuals with an identical genetic background (for example, the pres ence of the PNPLA3 I148M risk allele 96 ) and in response to similar injury (that is, fat overload).
DNA methylation. DNA methylation in particular is suggested to be involved in the progression of NAFLD towards advanced (fibrotic) clinical stages (FIG. 4) . Joined global expression and methylation analysis of human liver specimens demonstrated that advanced disease is associated with global deregulation (mostly hypo methylation) of methylation in multiple CpG sites 97 . Hypomethylation and increased expression of genes involved in tissue repair, regeneration and tumorigen esis were found, as were hypermethylated transcription ally repressed genes that are involved in basic metabolic functions (such as lipid, urea and amino acid metabo lism) or belonged to the cytochrome P450 family 97 . In addition, DNA hypomethylation was associated with transdifferentiation of stellate cells into myofibro blasts in cell models, a phenomenon commonly associated with fibrosis 98 . Abnormal methylation of the PNPLA3 promoter was associated with fibrosis severity in a large number of Japanese people 99 . Differences in the methyl ation status at specific CpG islands within the promoter of antifibrogenic (peroxisome proliferatoractivated receptorα (PPARA)) and PPARD) and profibrogenic (transforming growth factorβ1 (TGFB1), collagen type Iα1 (COL1A1) and plateletderived growth factorα (PDGFA)) genes might have a prognostic value in differentiating patients with mild fibrosis from those with advanced fibrosis 100 .
Liverspecific epigenetic changes that affect physio logical processes and lead to perturbations of normal hepatocyte and mitochondrial function not only affect the progression of NAFLD but also affect NAFLDrelated metabolic phenotypes, such as insu lin resistance. Targeted analysis of the methylation status of the PPARγ coactivator 1α (PPARGC1A) -a master transcriptional regulator of glucose and lipid metabolism and mitochondrial biogenesisshowed that methyl ation levels significantly correlated with plasma insulin levels, βcell function and the homeostatic model assessment of insulin resistance (HOMAIR) marker (calculated as (glucose mmol Nature Reviews | Disease Primers FAs can also cause 'intrinsic' cell death by placing stress on the endoplasmic reticulum (ER), leading to caspase-2-mediated cell death, in addition to Jun N-terminal kinase (JNK) activation, reactive oxygen species (ROS) production and mitochondrial dysfunction. In addition, FAs can cause mitochondrial stress directly by creating high demand for β-oxidation. This can also lead to excessive ROS production and mitochondrial dysfunction. Regardless of the pathway involved, FA-induced cell death leads to the release of damage-associated molecular patterns (DAMPs) into the extracellular space. c | Hepatic inflammation in fatty livers involves resident and recruited macrophages. These cells express Toll-like receptors (TLRs) and inflammasomes, which respond to DAMPs released from dead hepatocytes as well as other compounds in the local milieu, such as FAs and bacterial endotoxin from the intestine. Activation of these pathways stimulates the production of pro-inflammatory cytokines. Hepatic fibrosis in nonalcoholic steatohepatitis (NASH) is prompted by the activation of hepatic stellate cells to collagen-producing myofibroblasts. These cells express TLRs and, as such, are responsive to DAMPs and endotoxin; they are also stimulated by cytokines released by inflammatory cells. Stellate cells produce collagen, which results in liver fibrosis; they also produce leukocyte chemoattractants (not shown), which can cause a vicious cycle of inflammation and further fibrosis. TNF, tumour necrosis factor.
per litre × insulin mU per ml)/22.5) in humans 101 . A complex interaction between PPARGC1A mRNA levels and liver mitochondrial DNA (mtDNA) copy number was also reported. Interestingly, low mtDNA copy number was also directly associated with insu lin resistance and NAFLD 101 . Methylation of mtDNA might have a role in modulating the liver phenotype beyond genomic DNA 102 . Specifically, methylation and transcriptional activation of the mitochondrially encoded enzyme NADH dehydrogenase subunit 6 (encoded by MTND6), which is involved in oxida tive phosphorylation, in the liver was associated with moreadvanced liver pathology in humans 102 . A possible explanation for the changes in DNA methylation in NAFLD is its association with obe sity, which has been suggested to be associated with reduced DNA demethylation 103 . Furthermore, evidence suggests that the activity of 5 hydroxymethylcytosine (5hmC) might be an additional mechanism that explains liver DNA demethylation pathways in patients with NAFLD 104 . Epigenetic changes can be potentially inherited from one generation to the next. For instance, an experimental study in rodents showed that liver injury induced by the hepatotoxin carbon tetrachloride (CCl 4 ) led to hypomethylation in the PPARG promoter and associated chromatin modifications in sperm, stem cells and/or mature sperm 105 . Although this experimental study suggests that the hepatic woundhealing response might be heritable, it remains unknown whether the same is true in patients with NAFLD. In addition, epi genetic alterations acquired during develop ment may contribute to fetal metabolic programming 106 . Maternal protein restriction in mice led not only to fatty liver in the offspring but also to reduced lifespan; further in vitro analysis showed that these changes were associ ated with changes in DNA methylation 107 . Likewise, in utero overnutrition affects a sirtuinmediated his tone acetylase-deacetylase pathway that has an effect on the hepatic histone code of the progeny, as shown in a nonhuman primate experimental model of highfatdietinduced NAFLD 108 .
Non-coding RNAs. A large part (~60%) of the cellular gene expression machinery is regulated by noncoding RNAs -RNA transcripts that do not encode proteins (FIG. 4) . MicroRNAs (mi RNAs) have been studied exten sively in liver disease research, and evidence for their role in NAFLD is consistent. Numerous mi RNAs have been implicated in NAFLD severity, liver injury and lipid metabolism, including miR122, miR192, miR375 and miR34a [109] [110] [111] . Nature Reviews | Disease Primers Of particular importance in the pathophysiology of NAFLD is miR122, the expression of which is highly enriched in the healthy liver. Its network of regulated genes are involved in cholesterol metabolism 112 , modu lation of liver inflammation and progression of hepato carcinogenesis 113 . An in vitro study showed that miR122 regulates the production of collagen in hepatic stellate cells, suggesting a pivotal role in liver fibrogenesis 114 . Notably, the expression levels of miR122 are decreased in the liver of patients with NAFLD, whereas levels are increased in the circulating (extracellular) compart ment 111 ; mouse models of dietinduced steatohepatitis confirmed these findings 115 . This marked downregula tion of liver miR122 observed in NAFLD seems to be of particular relevance in the pathogenesis of the dis ease. In fact, silencing of mir-122 is an early event dur ing hepatocarcinogenesis as a consequence of NASH in humans 116 . Whether the downregulation of miR122 in the liver is the cause or the consequence of the progres sion of NAFLD remains to be investigated, because of the crosssectional nature of the abovementioned studies.
Several studies have explored the role of circulating (extracellular) miR122 levels as a biomarker of NASH -or disease progression -in humans, because miR122 levels significantly correlate with histological dam age (including hepatocyte ballooning and fibrosis) and increased liver enzymes (a marker for liver inflammation or injury) 111 . A twostage study, exploring a large panel of circulating mi RNAs at different stages of NAFLD, showed that circulating levels of miR122 were increased 7.2fold in patients with NASH versus healthy controls and 3.1fold in NASH versus simple steatosis 111 . Although the performance of circulating miR122 suggests that it could be a reliable biomarker of liver injury in NAFLD, the overall predictive value for liver fibrosis is very simi lar to currently available noninvasive measurements, including serum cytokeratin 18 levels 111 . Nevertheless, the research agenda is still open; for instance, prelimi nary data from a rat model of RouxenY gastric bypass showed that circulating miR122 levels decrease after sur gery, suggesting a putative role as a biomarker of response to therapeutic interventions 117 . Clinical evidence has sug gested that bariatric surgery was able to partially reverse epigenetic alterations in the liver associated with NAFLD. Notably, reversing differentially methylated sites in NAFLD correlates with improvement in liver histology 118 . Furthermore, miR122 released from the liver cir culate in the bloodstream -like a hormone -and is capable of integrating global metabolic signalling 111 . A functional polymorphism in the 3ʹ untranslated region of a validated miR122 target gene (that is, rs41318021 of solute carrier family 7 member 1 (SLC7A1)) was signifi cantly associated with arterial hypertension, suggesting that miR122 might potentially modulate the suscepti bility to increased blood pressure in people who carry the risk allele of this variant 111 . Moreover, the expression levels of liver miR122 significantly and negatively cor related with systolic arterial blood pressure 111 . Together, the reduction of miR122 levels in NAFLD might explain in part the connection between NAFLD and cardiovascular risk.
Finally, although the role of long noncoding RNAs in the pathophysiology of NAFLD remains largely unknown, they are implicated in lipid homeostasis. For instance, a liverenriched long noncoding RNA in mice regulates lipoprotein lipase activation through a farnesoid X receptor (FXR)mediated pathway 119 . 120, 121 . Obstructive sleep apnoea syndrome and psoriasis can be associated with NAFLD 122 . Apolipoprotein B and lysosomal acid lipase partial deficiency are rare famil ial causes of NAFLD and should be suspected in the absence of a clear association with components of meta bolic syndrome, although lysosomal acid lipase partial deficiency is usually associated with high levels of total and LDL cholesterol 123, 124 . As no specific marker is currently available, the diag nosis of NAFLD requires the exclusion of all the known other causes of chronic liver disease, haemochromatosis and autoimmune hepatitis and of other causes of steato sis, such as medications from AFLD, a threshold for daily alcohol intake has been set at <30 g for men and <20 g for women 125 , but a clear differentiation between the two is difficult in those patients who consume a slightly higher amount of alcohol (up to 40 g per day in both men and women).
Diagnosis, screening and prevention
Another important criterion is that NAFLD is tightly associated with metabolic syndrome and insulin resist ance in the liver, muscle and adipose tissues 126 . NAFLD should be suspected in all individuals with one or more components of the metabolic syndrome, defined as the cluster of any three of the following five features: increased waist circumference (ethnicity adjusted), increased fast ing glucose or T2DM, hypertriglyceridaemia, low HDL levels (sex adjusted) and increased blood pressure 127 . This association does not characterize NAFLD owing to the genetic variant in PNPLA3, but PNPLA3 mutation and metabolic syndrome may be associated; that is, frequently present in the same person 80 . Diagnostic workup should include evaluation of fam ily and personal history of components of the metabolic syndrome and assessment of liver tests, including plate let counts, albumin and coagulation, fasting blood glu cose, triglycerides and HDL levels. The most common modes of presentation of NAFLD are the detection of unexplained abnormal liver enzymes and/or of bright liver at ultrasonography.
Blood parameters.
Liver tests can show mild (twofold to fivefold) increases in the levels of ALT, alkaline phos phatase (ALP) and γglutamyltranspeptidase (GGT), but levels are normal in the majority of people with NAFLD (80%) 128 . The ratio of ALT to aspartate aminotransferase (AST) is greater than 1 unless advanced fibrotic NAFLD is present or the patient has covert AFLD. Increased levels of GGT do not discriminate between AFLD and NAFLD, as raised GGT levels are commonly associated with metabolic disease 129 . Ferritin may be increased in up to 60% of patients, but is mainly a marker of subclinical inflammation, given that iron overload is uncommon in NAFLD (4-6%) 130 . However, high ferritin levels (twofold to threefold) have been associated with moreadvanced disease 125 . Autoantibodies (antinuclear antibody and αsmooth muscle actinspecific antibody) are present in approximately onethird of patients at low titres (1/80 and 1/160) 131 as compared to absent in healthy individuals. A test of insulin sensitivity should be considered in all suspected patients. The HOMAIR is a good surro gate for insulin resistance in individuals who do not have diabetes 132 , although there is no universal agreement on threshold defining what is abnormal. Diagnostic workup should eventually include an oral glucose tolerance test according to standard criteria 133 that provides additional information about the glucose tolerance status.
Ultrasound-based techniques.
A quantitative ultrasound biomarker for hepatic steatosis is the controlled attenu ation parameter (CAP) 134 , which is a quantitative measure of the attenuation (energy loss) of the ultrasound beam as it traverses the hepatic parenchyma. The rationale is that ultrasound energy is attenuated more by fat than by nonfatty tissue; hence, greater attenuation implies greater fat content. The parameter is measured with the same device used in vibrationcontrolled transient elasto graphy (VCTE, see below) and is reported in units of dB per metre 134 . An anatomic image is not acquired, there fore, the location where the measurements were made is not recorded. Numerous singlecentre studies suggest that CAP can accurately identify patients with hepatic steatosis [135] [136] [137] . However, owing to overlap in CAP values across steatosis grades, CAP has limited accuracy for steatosis grading 135, 136 . In addition, the reproducibility of CAP values in patients with NAFLD has not been studied extensively. Although CAP shows promise, more data are needed before CAP can be considered a valid biomarker of hepatic steatosis.
MRI.
The leading quantitative MRI biomarker for hepatic steatosis is proton density fat fraction (PDFF) 138 . This biomarker measures the relative proportion of mobile protons that are attributable to fat and correlates closely with biochemically determined hepatic triglyceride con centration 138 . In numerous singlecentre and multicentre studies, PDFF has shown high accuracy for diagnosing, grading and longitudinally monitoring steatosis in adults and children, including individuals who are morbidly obese [139] [140] [141] [142] [143] [144] . Historically, measurement of PDFF required MRS, which is usually available only in academic centres and generally only assesses portions of the liver. In recent years, advanced MRI techniques have been developed that measure PDFF throughout the entire liver in a single breathhold, thereby eliminating sampling variability. These techniques are becoming commercially available on the latest generation of magnetic resonance scan ners made by the leading manufacturers. Importantly, PDFF measure ments made on scanners of different field strength and manufacturer agree closely [143] [144] [145] . With appro priate quality control, these advanced PDFFestimation techniques can be used in clinical trials (FIG. 5a) .
Diagnosis of NASH
The diagnosis of NAFLD can be derived from classic risk factor assessment along with biochemical measures, and ultrasoundbased and magnetic resonancebased detec tion of hepatic steatosis, yet the most relevant challenge to the clinician is the distinction between simple fatty liver and NASH because patients with NASH are at greater risk for developing progressive fibrosis. The presence of normal liver enzymes in the majority (80%) of individ uals renders the identification of patients at risk particu larly challenging 128 . Importantly, histological severity between patients with and those without abnormal liver aminotransferases does not differ.
The actual diagnosis of NASH requires microscopic evaluation of liver tissue, obtained by liver biopsy (FIG. 1) . Histological analysis shows the constellation of steato sis, hepatocyte ballooning and lobular inflammation, typically in acinar zone 3 -the microcirculatory unit through which blood exits the liver 146 . Fibrosis better pre dicts outcomes and mortality 7 . Semiquantitative grading and staging systems have been developed
. These systems are primarily used to the assess the severity of lesions. Grading involves the assessment of the activity of the disease: steatosis, inflammation and hepatocyte ballooning, whereas staging involves the assessment of fibrosis location and vascular remodelling. Although the grade might be reversible with appropriate intervention, the stage is probably less reversible.
As liver disease progression has been associated with persistence or worsening of metabolic risk factors 147 , most predictive indices of disease severity are based on components of the metabolic syndrome along with bio chemical and imaging indicators of advanced liver dis ease. However, the large number of patients with NAFLD and the risk of complications associated with liver biopsy have led to the refinement of noninvasive techniques to predict the histological features of NAFLD and NASH.
In clinical practice, interpretation of noninvasive markers should be performed by hepatologists accord ing to the clinical context and considering all the other clinical and laboratory findings. The combination of two unrelated markers is recommended, as no single test has an advantage over the others in the prediction of the severity of liver disease 148 . Among the different strat egies, algorithms that combine transient elasto graphy and serum biomarkers are the most attractive and vali dated 148 . However, in case of unexplained discordance of noninvasive tests, a liver biopsy should be performed.
Biomarkers and scores.
Screening of steatosis is usually based on ultrasonography in individual patients, but indi ces or biomarkers are preferred in largerscale screening studies. The bestvalidated biomarkers are the Fatty Liver Index, the SteatoTest and the NAFLD liver fat score. Simple steatosis does not increase liverrelated mortality, but these biomarkers can variably predict metabolic and cardiovascular outcomes or mortality 149 . Serum mark ers of fibrosis seem to have a better performance, par ticularly the NAFLD Fibrosis Score (NFS), Fibrosis4 (FIB4), BARD and commercially available panels, such as FibroTest, FibroMeter and the Enhanced Liver Fibrosis (ELF) test 150 (TABLE 3) . All of these tools have acceptable diagnostic accuracy, but only NFS and FIB4 have been extensively validated 19 . All of these tests perform best at excluding severe fibrosis -cirrhosis, with negative predict ive values of >90%, but are typically less accurate in the determination of lesssevere fibrosis 150 . NFS, FIB4, ELF and FibroTest can also predict overall, cardiovascular and liverrelated mortality 149 .
Several noninvasive procedures have been tested for the noninvasive prediction of NASH. Plasma levels of cytokeratin 18 fragments (a marker of apoptosis) had a promising performance, but recent data have highlighted the limited accuracy 151 and to date no recommendation can be issued for the noninvasive diagnosis of NASH.
Ultrasonography. Conventional ultrasonography, in which standard Bmode (grey scale) ultrasonographic images are acquired and interpreted qualitatively, is fre quently used to screen for hepatic steatosis, but conven tional ultrasonography is insensitive to mild steatosis, especially in individuals who are obese, and is limited by reader variability 152, 153 .
Elastography. Imaging techniques that are collect ively known as elastography have been developed to in directly measure tissue stiffness noninvasively. The measurement involves the assessment of the propa gation of shear waves within the liver, from which the hepatic stiffness is inferred. Depending on the device, results can be reported as shear wave speed in metres per second or as one of several elastic moduli (for example, Young modulus or complex shear modulus) in kPa 154 . These various elastographyderived parameters have emerged as the leading imaging biomarkers of hepatic fibrosis, but like serum markers, they perform best only at detecting advanced (stage 3 or stage 4) fibrosis.
Ultrasound-based elastography. The first ultrasound based method to measure liver stiffness was VCTE 155 . This technology uses a nonimaging device to track shear waves that are transmitted transiently into the liver by an external vibration source; an anatomical image is not acquired and the location from which the measurements are made is not recorded.
More recently, elastography capabilities have been added to clinical ultrasound scanners 154 . Elastography enabled scanners use ultrasound to track shear waves that are generated transiently in situ within the liver by an ultrasound push pulse (also known as an acoustic radi ation force impulse); measurement locations are recorded on an anatomical image 154, 156, 157 (FIG. 5b) . As each manufac turer uses proprietary hardware and software, measure ments made with different devices and even with different transducers (probes) on the same device do not agree 157, 158 . Thus, any given patient should be monitored serially with a single device and using the same probe. VCTE and elastography enabled scanners have been shown to provide high accuracy for the diagnosis of advanced fibrosis in patients with viral hepatitis infection 159, 160 . Singlecentre studies suggest these devices also accurately diagnose advanced fibrosis in patients with NAFLD 160 , although multicentre validation studies have not yet been performed. None of these devices can diagnose early fibrosis accurately. The technical success rate, reliability, robustness and precision of these devices for measuring stiffness parameters in NAFLD has not been extensively studied, and their performance in detecting changes in fibrosis in the context of treatment trials is unknown 157 . Until such data become available, caution is advised for use of these devices in NAFLD clinical trials.
Magnetic resonance-based elastography. Magnetic reso nance elastography uses a specialized MRI sequence to visualize shear waves that are delivered continuously into the liver by an external acoustic source 161 . The wave images are processed by a socalled inversion algor ithm to generate 'elastograms' (REF. 162) (FIG. 5c) . These computergenerated images depict the spatial distrib ution of a stiffness parameter known as the magnitude of the complex shear modulus (usually referred to as 'shear stiffness' in the medical literature). The hepatic stiffness is recorded from representative portions of the liver. Magnetic resonance elastography is now commer cially available on commercial MRI scanners, with the same hardware to generate the shear waves and the same inversion algorithm to process the wave images. Small singlecentre studies in healthy volunteers suggest that measurements made with different scanners agree 163 . Large studies in patients with NAFLD are needed to confirm crossplatform reproducibility.
In singlecentre studies, magnetic resonance elasto graphy has been shown to diagnose advanced fibrosis in adult NAFLD with high accuracy [164] [165] [166] . The accuracy of magnetic resonance elastography is probably higher than that of ultrasoundbased elastography 167 . As with ultra soundbased techniques, accuracy for the detection of early fibrosis is modest. The precision of magnetic reso nance elastography in the NAFLD population has not been studied extensively. Multicentre validation studies are needed before magnetic resonance elastography can replace biopsy in NAFLD clinical trials.
Follow-up monitoring
Patient monitoring should include routine bio chemistry, noninvasive monitoring of fibrosis and the assessment of comorbidities. Given that the risk of developing T2DM and cardiovascular complications is increased in patients with NAFLD 122 , oral glucose tolerance tests should be performed whenever glucose metabolism is abnormal (that is, a fasting glucose of 100-126 mg per dl; glycated haemoglobin (HbA1c) of 5.7-6.4%) 133 and carotid doppler ultrasonography 122 ; referral to other specialists might be required. The timing of followup testing is still debated, and a definite evaluation for risks . Although the NAFLD Activity Score is known to closely correlate with a diagnosis of NASH, it was created for clinical trials to assess changes in the components and has been shown to be associated with liver tests (alanine aminotransferase and aspartate aminotransferase), whereas the pathologist's diagnosis of NASH associates with features of insulin resistance. The pathologist is encouraged to make a separate, pattern-based diagnosis in addition to scoring the lesions. ‡ Delicate psf requires trichrome staining, whereas dense psf can be visualized on a haematoxylin and eosin stain first. § A primary difference between the European algorithm and the NASH CRN is that the former score was derived to establish a diagnosis of NASH. Steatosis of >1, activity of >2 (with both ballooning and lobular inflammation of >1) equals NASH 228 .
of progression and costs associated with investigations has not yet been performed. In patients with simple fatty liver, a reasonable approach is a follow up in pri mary care setting, unless worsening of metabolic risk factors occurs. In patients with NASH and/or fibrosis, a yearly monitoring policy is advisable. If indicated, on a casebycase basis a repeat biopsy could be performed after 5-7 years.
Management
Current management of NAFLD The first step in the management of NASH in most patients is the implementation of lifestyle modifications that focus on healthy eating habits and regular exercise 168 . Without biopsy confirmation of the presence of NASH, lifestyle modification is still appropriate to reduce cardio vascular risks in patients with NAFLD and also to treat NASH if it is present. Weight loss for patients who are overweight and obese is recommended based on the collect ive observations from multiple studies showing that histological improvement can occur when patients lose 5-10% of their body weight 169, 170 . Unfortunately, meaningful lifestyle modification is difficult to achieve and difficult to sustain for most people 171, 172 and, therefore, alternatives are needed to treat NASH and to prevent the associated complications of the metabolic syndrome. At this time, no pharmaceutical treatments are approved for NASH, although many agents are in various stages of evaluation in clinical trials. Bariatric surgery is a good option for select patients who are obese and have NASH as it typically leads to improvement in NASH 173, 174 .
Pathogenesis-based targets of therapy As reviewed above, one perspective on the pathogenesis of NASH is that lipotoxic lipid species, which are derived from an excess supply of fatty acids in hepatocytes, mediate cellular injury and the resulting inflammatory and fibrotic response that results in the histological phenotype of NASH [175] [176] [177] . This paradigm enables us to predict therapeutic interventions that might prevent or treat NASH by targeting the oversupply of fatty acids to the liver, the generation of lipotoxic intermediates and the resulting dysfunctional cellular responses (FIG. 6) . Given that the best treatments of disease are those that target underlying causes at a fundamental level, an ideal approach would be to pharmacologically manipulate the pathways of energy metabolism that are responsible for the heterogeneity in human energy efficiency. Generally, the performance of a non-invasive diagnostic method is evaluated by the area under the receiver operator characteristic curve (AUROC), taking liver biopsy as the reference standard, in which a value of 1 reflects a 'perfect' test with 100% sensitivity and specificity and a value of 0.5 reflects a test as good as chance. ALT, alanine aminotransferase; apoAI, apoprotein AI; AST, aspartate aminotransferase; BG, fasting blood glucose; BIL, total bilirubin; BMI, body mass index; CHOL, fasting cholesterol; CV, cardiovascular; GGT, γ-glutamyl-transpeptidase; HA, hyaluronic acid; MetS, metabolic syndrome; NA, not available; NAFLD, nonalcoholic fatty liver disease; NPV, negative predictive value; PIIINP, amino-terminal propeptide of type III collagen; PNPLA3, patatin-like phospholipase domain-containing protein 3; PPV, positive predictive value; T2DM, type 2 diabetes mellitus; TG, fasting triglycerides; TIMP1, tissue inhibitor of metalloproteinase 1; WC, waist circumference.
If the genomic or epigenetic changes responsible for these differences can be identified and exploited, then treatments could be effective for NASH as well as the underlying insulin resistance, hypertension, hyperlipid aemia and other manifestations of the metabolic syn drome that lead to disability and early death 178 . Animal studies have provided some insights into these differences, but how these will be translated into treatment of human disease is yet to be shown. Examples include the diver gence of rat strains into those having high and low exer cise tolerance, with features of the metabolic syndrome developing in the latter 179 , the role of βadrenergic stimu lation of highly metabolic brown adipose tissue 180 , the role of serotonin in modulating metabolism 181 and the role of peripheral cannabinoid signalling in modulating energy efficiency 182 . At this time, insights into the regulation of energy metabolism are mostly at early preclinical stages, and clinical trials have generally focused on manipulating more downstream processes, such as lipogenesis, lipolysis, inflammation, oxidative stress and fibrogenesis.
Preventing an oversupply of fatty acids in the liver Inhibition of DNL. One approach to reducing lipotoxic liver injury is to reduce the endogenous production of fatty acids in the liver by inhibiting DNL. The transcrip tion factor SREBP1C is a major regulator of DNL; thus, treatments that decrease SREBP1C may be beneficial. This is one potential mechanism by which the bile acid derivative obeticholic acid may work. As an activating ligand for the nuclear receptor FXR, obeticholic acid increases the expression of tyrosineprotein phosphatase nonreceptor type 6 (PTPN6; also known as SHP1), which decreases the expression of SREBP1C 183 . A Phase II clinical trial of obeticholic acid has demonstrated histo logical improvement in NASH after 72 weeks (45% versus 21% in placebotreated patients; P = 0.0002) 184 . However, treatment was associated with significant pruritus in 23% in the treatment group compared with 6% in the placebo group, and with an increase in total and LDL cholesterol and a decrease in HDL cholesterol in treated patients, the importance of which will be further assessed in another clinical trial.
Another approach to inhibiting DNL includes using inhibitors of key enzymes in the pathway of fatty acid synthesis, such as acetylCoA carboxylase, and such agents are being evaluated in clinical trials. Augmenting the incretin axis with glucagonlike peptide 1 (GLP1) analogues such as exenatide or impairing the breakdown of endogenous GLP1 with the dipeptidyl peptidase 4 inhibitors (gliptins) may also decrease hepatic lipo genesis by decreasing substrate availability; this approach is also being examined in clinical trials. Reducing the burden of fatty acids delivered to the liver. Lipolysis of stored triglyceride in adipose tissue is the main source of fatty acids delivered via the circulation to the liver. Adipose tissue lipolysis is normally sup pressed by insulin, but when adipose tissue is insulin resistant, it continues to release fatty acids into the blood at inappropri ate times and thus contributes to the development of NASH 185 . The PPARγ ligands thiazo lidinediones (TZDs or 'glitazones') have been shown to improve adipocyte insulin responsiveness and thus decrease inappropriate lipolysis. One TZD, pioglitazone, has been shown to improve adipose insulin sensitivity and improve NASH 186, 187 . Unfortunately, this benefit comes at the expense of increased body weight in some patients because of adipocyte triglyceride retention. This and possibly other adverse effects such as osteo porosis and bladder cancer have dampened the enthu siasm for using pioglitazone for NASH and it has not gained widespread use.
Metformin is another insulin sensitizing agent but its effect is primarily in the liver. There is little evidence that hepatic insulin resistance has a role in causing NASH. A large randomized clinical trial (RCT) of metformin in children did not show any benefit on ALT levels or histology but fortunately neither did it show worsen ing 188 . Nonetheless, metformin may have an adjunctive role in the treatment of NASH because it is often associ ated with weight loss, and recent data indicate that it is associated with a reduced risk of several malignancies 189 . Fatty acids and the carbohydrates used to make fatty acids can also be diverted to oxidative pathways and this may explain the benefit of regular exercise in improving the metabolic syndrome. Oxidative pathways can also be stimulated pharmacologically. The PPARα and PPARδ ligand GFT505 was recently evaluated in a clinical trial because it improves insulin sensitivity, which may be explained by the effect of PPARα in promoting oxida tive metabolism in the liver and PPARδ in promoting oxidative metabolism in muscle 190 .
Reducing injury
The mechanisms of lipotoxic injury remain uncertain, but oxidative stress has been proposed to have a role 191 .
Oxidative stress with associated lipid peroxidation clearly occurs in NASH 192 , but whether it is causative or an epiphenomenon remains unknown. Two large RCTs of natural vitamin E (dαtocopherol) at a dose of 800 IU daily have been conducted: one in adults (PIVENS) and one in children (TONIC). The PIVENS trial demon strated improvement in liver histology in 43% com pared with a placebo response of 19% (P = 0.001) 187 , and similarly the TONIC trial showed resolution of NASH in 58% compared with 28% in placebo (P = 0.006) 188 . Neither trial showed evidence that indices of oxidative stress improved, so it remains somewhat unclear how vitamin E improves NASH. Both the PIVENS and the TONIC trials were conducted in patients without dia betes or cirrhosis, therefore, the benefits of vitamin E in patients with these commonly associated condi tions remain unknown. Concern has been raised about the cardiovascular safety of highdose vitamin E and, consequently, patients and doses should be carefully selected. The ideal patient may be someone with aggres sive NASH and no diabetes or major risks for cardio vascular disease, but such patients comprise a relative minority. It should be noted that weight loss has an addi tive benefit in patients treated with vitamin E, so the use of vitamin E should be an adjunct to weight loss and not an alternative 193 . Fish oil (polyomega3 fatty acids) may also exert beneficial effects on lipid peroxidation, but a large trial of ethyleicosapentaenoic acid in patients with NASH did not show any benefit 194 . Endoplasmic reticulum stress is another process known to occur in NASH that may be central to the pathogenesis of lipotoxic hepatocyte injury. Studies of agents that diminish the endoplasmic reticulum stress response have provided provocative data in animals but these have yet to be introduced into RCTs 195 . The contribution of hypercholesterolaemia to the development of steatohepatitis and liver fibrosis has not been fully established, but several studies suggest that it may have a role in some patients. A morphometric study of liver biopsies demonstrated cholesterol crys tals in lipid droplets in patients with steatohepatitis but not steatosis 196 . Statin use is safe in patients with liver disease 197 , and a Cochrane review concluded that statins can improve steatosis and reduce the levels of aminotransferase, but treatment trials with histologi cal endpoints are lacking 198 . More recently, in a large European observational cohort with NAFLD, statin use was associated with less steatosis, NASH and fibrosis in a dosedependent manner; interestingly, the presence of the PNPLA3 I148M polymorphism prevented the protective effect of statins 199 . In another recent study, statin use in patients with NAFLD was associated with a reduction in liverrelated deaths, liver transplantations or other liver outcomes 7 .
Inhibition of inflammation
The role of inflammation in contributing to hepatocyte injury versus a consequence of injury is unknown but should be clarified by the results of clinical trials examin ing various antiinflammatory approaches. One clinical trial of an antiinflammatory phospho diesterase type 4 inhibitor was negative despite the demonstration of reduced circulating tumour necrosis factor levels in patients given the active agent 200 . However, like all contributors to the pathogenesis of NASH, inflamma tion may have an important role in only a subgroup of patients. Posthoc analysis of RCT results to identify and then predict responders to a specific therapy will be essential for all agents.
Inhibition of apoptosis
Caspase inhibitors have been developed and are being explored in RCTs for numerous diseases including NASH based on the recognized role of hepatocyte apoptosis in the pathogenesis of NASH 201 . Although this might be a rational approach in acute processes, theo retical concerns about the safety of longterm inhib ition of apoptosis persist with this treatment approach in NASH.
Inhibition of fibrosis
In the absence of effective therapy for NASH, being able to prevent the progression of fibrosis to cirrhosis would be advantageous. Even when effective NASH therapies are identified, there may be a role for shortterm use of effective antifibrotic agents to accelerate the reversal of fibrosis. No antifibrotic agents for liver disease are avail able but several are being explored in RCTs, including an antilysyl oxidase homologue 2 (LOXL2) antibody and a galectinbinding molecule that have shown early promise.
Quality of life QOL in patients with NAFLD is understudied, although its importance is substantial and broadens our under standing of the overall burden of the disease
. Several studies have reported QOL scores in the con text of NAFLD [202] [203] [204] . Overall findings have been similar and suggest that NAFLD is associated with a reduced overall but predominately physical healthrelated QOL (HRQOL). Some data suggest that the impairment in QOL reported in patients with NAFLD may be beyond that reported in other aetiologies of liver disease 202, 203 . In a sample of 771 patients with biopsyconfirmed NAFLD from the NASH Clinical Research Network database, QOL as measured by the ShortForm 36 Health Survey questionnaire was compared to a United States reference population with or without chronic disease 205 . In this study, impaired QOL was most evident in p hysical health, with mental health affected to a lesser degree.
Most patients with NAFLD are overweight or obese, and even in those who are not, lifestyle changes that incorporate dietary modification and exercise are the cornerstone of therapy. Obesity has both health and psycho social ramifications and can have a profound effect on an individual patient's QOL. In a crosssectional study, obesity was not associated with lower QOL 205 ; however, the effects of imposing lifestyle change were not measured. One study evaluated the effect of weight loss on HRQOL in patients with NAFLD and found that, compared with those who did not lose weight, those that did had improved HRQOL scores over baseline values, comparable to the general population 204 . A prospective study of intensive lifestyle intervention showed that patients who lost >7% body weight benefited not only from improvement or resolution in steatosis, necro inflammation and cellular ballooning (NASH resolu tion) but also improvement or resolution in fibrosis 170 . Importantly, no patient who lost >7% body weight had progression of fibrosis. In those that lost >10% body weight, fibrosis improved in 81%, although overall numbers were small as was baseline extent of fibrosis. Weight loss and dietary change are hard to achieve and even harder to maintain, particularly in the case of mor bid obesity. Not only is behavioural change difficult in itself but also barriers -physical, social and economic (among others) -can pose a challenge to accomplishing them effectively.
Bariatric surgery for NASH Compared with patients who are obese and are matched for comorbidities, those that undergo bariatric surgery have decreased longterm mortality [206] [207] [208] . The largest effect on mortality comes from a reduction in myo cardial infarction and malignancy -the two most com mon causes of death in patients with NAFLD. Bariatric surgery can be an effective and appropriate treatment strategy for a subset of patients with NAFLD, including those with advanced fibrosis and even carefully selected patients with compensated cirrhosis who meet criteria for bariatric surgery 4, 209 . While it is important to note that bariatric surgery has not been studied prospectively specifically as a treatment for NASH, the bestavailable data demonstrate that bariatric surgery in patients with NASH is safe and improves NASHrelated liver disease, including fibrosis 174 . The liverrelated benefits derived from bariatric surgery such as RouxenY gastric bypass or sleeve gastrectomy extend beyond weight loss. Both procedures increase the levels of GLP1, which decreases appetite, slows gastric emptying and improves insulin sensitivity. Furthermore, GLP1 affects the modula tion of bile acid signalling, specifically through FXR, which can alter the gut microbiota and can have other potential benefits [210] [211] [212] . However, practitioners and patients are reluctant to pursue bariatric surgery, even when patients are appro priate candidates. Although there are known complica tions that vary according to the procedure performed, the overall risk is low in properly selected patients 213 . Although carefully selected patients with established compensated (that is, stable without profound abnor malities in liver function) cirrhosis can safely undergo bariatric surgery, cirrhosis is associated with a higher risk of post operative complications, including hepatic decompen sation (that is, the develop ment of ascites, hepatic encephalopathy or variceal bleeding) 207 . There fore, careful patient selection cannot be overemphasized. Success of the intervention requires that patients remain committed to necessary lifestyle changes postoperatively to avoid regaining lost weight. More importantly, compli ance with recommendations and followup are impera tive to avoid metabolic and nutritional problems that are related to malabsorption or other consequences of bariatric surgery 214 .
Box 3 | Affected quality-of-life aspects in NAFLD
Physical health scores • People with nonalcoholic steatohepatitis (NASH) have poorer scores than patients with non-NASH nonalcoholic fatty liver disease (NAFLD) 205 • NAFLD as an aetiology may have lower health-related quality-of-life (HRQOL) scores than other aetiologies of liver disease 202, 203 • Patients with cirrhosis have poorer scores than patients with no or some fibrosis 202, 203 • Weight loss in people with NAFLD may improve QOL scores 
Bariatric surgery
• Improves overall survival in obesity 170, [204] [205] [206] [207] • Is safe in patients with NASH Welzel and colleagues estimated the population attributable fraction (PAF), otherwise stated as the pro portion of cases that can be attributed to specific risk fac tors, in patients with HCC from various causes of liver disease using the SEERMedicare databases from 1994 to 2007 (REF. 218 ). Analysis of a cohort of 6,991 people showed that those with obesity and diabetes (presum ably with NAFLD) had the highest PAF of HCC (36.6%) compared with other aetiologies, in descending order of magnitude: alcohol intake (23.5%), hepatitis C virus infection (22.4%), hepatitis B virus infection (6.3%) and other (3.2%). An important limitation of this study is that patients did not have a biopsy diagnosis of NAFLD or NASH. The PAF takes into account disease preva lence; thus, if NAFLD were to be eliminated, the effect on HCC would be substantial. However, the risk estimate of HCC in an individual patient with NAFLD is only in the order of 1.5-2.5 compared with 20-25 in a patient with hepatitis C virus infection. Per annum rates of HCC development in patients with NASH are lower than for patients with hepatitis C virus infection (2.6 versus 4) 21 .
As NASH is so prevalent, it is not surprising that HCC as an indication for liver transplantation has increased 3.64fold in patients with underlying NASH and a BMI of >30 kg per m 2 . In comparison, HCC due to hepati tis C virus has increased only 2.25fold over a 10year period from 2002-2012. Whereas diabetes and obesity are independent risk factors for HCC, the increase in NASHrelated HCC persisted after controlling for these variables 219 . Although older age, obesity, T2DM and male sex are risk factors for the development of HCC, NASH does seem to contribute independently 218, 220 . Cirrhosis creates a milieu that is permissive for the development of HCC; thus, current screening recom mendations focus primarily on patients with cirrhosis. However, reports of HCC occurring in the absence of cirrhosis are on the rise, with some even developing in the absence of profound fibrosis. By some estimates, 10-75% of cases of HCC may occur in noncirrhotic NAFLD 221, 222 . This is a serious problem because of the large number of patients affected by NAFLD and NASH at a population level. The individual risk of HCC in patients without cirrhosis who have NAFLD is even less well understood. Consequently, although some individuals at risk for HCC may not be identified at an early stage of malignancy, there is presently insufficient evidence to alter current screening guidelines. Optimal recommendations for HCC screening in patients with NAFLD may change in the future as more is learnt about individual risk in this challenging population.
Outlook
Both the shortterm and the longterm outlook for NAFLD will evolve as clinical and basic research continue to redefine the field
. NAFLD is an extremely com plex and nuanced disease that represents the convergence of many pathways, risk factors and external influences that are not uniform in all patients. Therefore, it seems likely that NAFLD represents a constellation of various phenotypes that will require study from many angles as illustrated in this Primer. NAFLD is highly prevalent, yet only a minor subset of patients progress to advanced liver disease, including HCC. Although many patients with NAFLD have a common metabolic profile (T2DM, hypertension and obesity, among others), not all patients do. The underlying pathophysiology of NAFLD and in particular NASH is strongly linked to insulin resistance, aberrant hepatic lipid metabolism, visceral adiposity and inflammation. However, several other important modu lators of disease, such as the environment and diet, can further modify triggers of chronic extrahepatic and intra hepatic immune pathways 223 and the pathogenetic roles of gut dysbiosis [224] [225] [226] . The extent to which these factors drive disease progression and outcomes will be clarified as we gain further insight into the amassing data in this increasingly important area of research.
Furthermore, differences in genetic susceptibility as well as epigenetics may help to better understand atrisk populations. Therefore, a more indepth evaluation of these differences will allow us to better understand the phenotypes of NAFLD. In turn, a more sophisticated abil ity to phenotype patients with NAFLD will further clarify expensive and imperfect 'gold-standard' liver biopsy for the detection and severity evaluation of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), including advanced fibrosis • Serum-based algorithms as markers for liver injury and fibrosis 19, [229] [230] [231] [232] [233] • Imaging-based system to detect the constellation of lesions that collectively comprise NASH
Management
• Lifestyle intervention, including management of meal content and portions, and exercise programmes • Therapeutic treatments based on a better understanding of the mechanisms of liver injury from the underlying and closely related links of overweight, obesity and insulin resistance differences in disease progression between patients and permit a more personalized approach to therapy. Animal models of disease have offered tremendous insight into relevant mechanisms, but to date, no ani mal model has faithfully replicated all aspects of the human condition. However, this benchmark may not be compulsory or attainable given the heterogeneity of the human disease.
Just as the pathophysiology of NAFLD is not the same in all patients, treatment will need to be individualized. With rare exception, a commitment to lifestyle modifica tion should be the foundation of any treatment plan, but this is not sufficient for most patients. In the morbidly obese or in those with severe comorbid illness, bariat ric surgery may have substantial benefit. Many patients will require moreintense intervention -behavioural and pharmacological.
Until recently, the landscape of clinical trials for NASH was somewhat limited. Currently there are hun dreds of clinical trials in NASH. The breadth of mech anisms being targeted reflects the complexity of the disease. As the field continues to advance and patients can be better classified by constellations of risk factors, or subclassifications using genomics or metabolomics, we will be able to offer a more personalized, mechanistically derived treatment approach to each patient.
